2. Autophagy
  3. Autophagy
  4. Anti-Human/Mouse LY6E Antibody (9B12)

Anti-Human/Mouse LY6E Antibody (9B12) 

Cat. No.: HY-P992056
Technical Support

Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8+ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8+ T cells strictly depends on the presence of PILRα, and it does not affect CD4+ T cells or T cell development in the thymus, exhibiting high specificity.

For research use only. We do not sell to patients.

Anti-Human/Mouse LY6E Antibody (9B12)

Anti-Human/Mouse LY6E Antibody (9B12) Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anti-Human/Mouse LY6E Antibody (9B12) Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8+ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8+ T cells strictly depends on the presence of PILRα, and it does not affect CD4+ T cells or T cell development in the thymus, exhibiting high specificity[1][2][3].

Species Reactivity

Human/Mouse
In Vitro

Anti-Human/Mouse LY6E Antibody (9B12) binds to human LY6E with an average Kd of 3.7 nmol/L and to cynomolgus monkey LY6E with an average Kd of 6.9 nmol/L[2].
Anti-Human/Mouse LY6E Antibody (9B12) (5 μg/mL; 30 min, 2 h) is internalized into KURAMOCHI ovarian cancer cells within 30 minutes (via a lipid raft-dependent, clathrin-independent pathway) and into HCC1569 breast cancer cells within 2 hours, colocalizing with lysosomal compartments in both cell types[2].
Anti-Human/Mouse LY6E Antibody (9B12) detects low, moderate, and high surface LY6E expression via flow cytometry on DOV13, COV362, and KURAMOCHI ovarian cancer cells, respectively, matching their corresponding LY6E copy numbers[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Human/Mouse LY6E Antibody (9B12) Related Antibodies

Immunofluorescence[2]

Cell Line: human ovarian cancer KURAMOCHI cells, human breast cancer HCC1569 cells
Concentration: 5 μg/mL (KURAMOCHI cells)
Incubation Time: 30 min (KURAMOCHI cells); 2 hours (HCC1569 cells)
Result: Was internalized into live KURAMOCHI cells within 30 minutes, colocalizing with late endosomal/lysosomal marker LAMP1.
Internalization into KURAMOCHI cells was inhibited by 1 mmol/L methyl β cyclodextrin but not by 25 μmol/L chlorpromazine.
Was endocytosed to the lysosomes of HCC1569 cells within a 2-hour period.
In Vivo

Anti-Human/Mouse LY6E Antibody (9B12) (0.5-8 mg/kg; i.v.; single dose) conjugated to MMAE achieves 80% partial responses and 10% complete responses in SU.86.86 pancreatic cancer xenografts, with higher doses driving sustained near-complete tumor regression[2].
Anti-Human/Mouse LY6E Antibody (9B12) (1-6 mg/kg; i.v.; single dose) conjugated to MMAE achieves 80% partial responses with 1 month of sustained tumor regression in SW900 NSCLC xenografts, with higher doses driving sustained near-complete tumor regression[2].
Anti-Human/Mouse LY6E Antibody (9B12) (2-12 mg/kg; i.v.; single dose) conjugated to MMAE achieves 80% partial responses and 20% complete responses in PAXF 1657 pancreatic cancer patient-derived xenografts, with higher doses driving sustained near-complete tumor regression[2].
Anti-Human/Mouse LY6E Antibody (9B12) (2-12 mg/kg; i.v.; single dose) conjugated to MMAE achieves 100% complete responses in HBCx-9 triple-negative breast cancer patient-derived xenografts with heterogeneous LY6E expression, with sustained tumor regression lasting 25 days post-dose[2].
Anti-Human/Mouse LY6E Antibody (9B12) (4-12 mg/kg; i.v.; single dose) conjugated to MMAE achieves 40% partial responses in MAXF 1162 HER2-positive breast cancer patient-derived xenografts, with higher doses driving complete responses[2].
Anti-Human/Mouse LY6E Antibody (9B12) (200 μg; i.p.; every 3 to 4 days; 15 days) disrupts CD8+ T cell quiescence and reduces CD8+ T cell survival in peripheral lymphoid organs of B6 WT mice, with no effect on CD4+ T cells[3].
Anti-Human/Mouse LY6E Antibody (9B12) (200 μg; i.p.; every 3 days; 14 days) reduces CD8+ T cell survival in peripheral lymphoid organs of thymectomized B6 WT mice, confirming effects are independent of thymic T cell development[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C.B-17 SCID (female, 4-6 weeks old, subcutaneous inoculation with SU.86.86 pancreatic cancer cells)[2]
Dosage: 0.5 mg/kg; 1 mg/kg; 2 mg/kg; 4 mg/kg; 8 mg/kg
Administration: i.v.; single dose
Result: Achieved 8 of 10 partial responses and 1 of 10 complete responses at 2 mg/kg.
Induced sustained, near-complete tumor regression through the 40-day study period at 4 mg/kg and 8 mg/kg.
Animal Model: C.B-17 SCID beige (female, 4-6 weeks old, subcutaneous inoculation with SW900 squamous NSCLC cells)[2]
Dosage: 1 mg/kg; 3 mg/kg; 6 mg/kg
Administration: i.v.; single dose
Result: Achieved 8 partial responses with tumor regression lasting for about 1 month post-dose at 1 mg/kg.
Induced sustained, near-complete tumor regression through the 40-day study period at 3 mg/kg and 6 mg/kg.
Gene ID

4061  [NCBI]

Accession

Q16553
Target

Ly6E
Application

ELISA, FACS, Functional assay, Research in vivo
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[Anti-Human/Mouse LY6E Antibody (9B12)]
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anti-Human/Mouse LY6E Antibody (9B12) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Human/Mouse LY6E Antibody (9B12)Autophagymouse paired immunoglobulin-like type 2 receptor alphahuman LY6Elipid raftlysosomesCD8+ T cellscynomolgus monkey LY6Ehepatoma cellspatient-derived xenograft modelsinsulin-degrading enzymeperipheral lymphoid organsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anti-Human/Mouse LY6E Antibody (9B12)
Cat. No.:
HY-P992056
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.